Vincenzo Libri is Professor of Translational Neurology at UCL-Institute of Neurology (ION) and Director of the NIHR UCLH Clinical Research Facility and the Leonard Wolfson Experimental Neurology Centre (LWENC). He is also founding Director of the MRes in Translational Neuroscience at UCL-ION, Director of the Covid-19 Vaccine Trial Centre at UCLH and Chair of the Health Research Authority-London Chelsea Research Ethics Committee.
He has long lasting expertise in clinical pharmacology, translational neurology and early phase clinical trials across diseases. Between 1994 and 1998, he was Lecturer in Pharmacology at the University of Rome, Italy. From 1998 to 2008, he undertook leadership for translational medicine and early phase clinical trials in multiple Pharmaceutical Companies (GlaxoWellcome, Eli Lilly and GlaxoSmithKline). From 2009 to 2013, he was Head of Clinical Studies at the NIHR Clinical Research Facility, Imperial College London, overseeing the running of the Centre and managing the whole portfolio of clinical studies.
He is Principal Investigator/Co-investigator of several early phase clinical trials in neurodegenerative diseases, including antisense oligonucleotide (ASO) trials in ALS patients with single gene mutations (namely C9ORF72). He represents UCLH on the Biogen NeuroNetwork Board, allowing the LWENC to be selected for preferential allocation of ASO Phase I trials.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.